Inici › Càncer de pròstata › Massachusetts › Boston
Assaigs clínics de Càncer de pròstata a Boston, MA
59 estudis de Càncer de pròstata busquen participants en centres de Boston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutantFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Reclutant
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutantFase 1
- Massachusetts General Hospital, Boston
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
ReclutantFase 4
- Massachusetts General Hospital, Boston
Precision-Based Genomics in Prostate Cancer
ReclutantEstudi observacional
- Dana Farber Cancer Institute, Boston, MA, Boston
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Reclutant
- Dana Farber Cancer Institute, Boston
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
ReclutantFase 1/2
- Research Site, Boston
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
ReclutantFase 1/2
- Dana Farber Mass General Brigham Cancer Care Inc, Boston
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1
- Harvard Medical School-Massachusetts General Hospital, Boston
Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes
Reclutant
- Dana-Farber Cancer Institute, Boston
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
ReclutantFase 2/3
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
ReclutantFase 1
- Mass General Hospital, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
ReclutantFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
ReclutantFase 3
- Beth Israel Deaconess Med Center, Boston
- Dana Farber Cancer Institute, Boston
CV CARE: CardioVascular Care in PC Patients
Reclutant
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
ReclutantFase 3
- Beth Israel Deaconess Medical Center ( Site 0043), Boston
- Dana Farber Cancer Institute ( Site 0012), Boston
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1
- Dana-Farber Cancer Institute, Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
ReclutantFase 3
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
Reclutant
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Serial MRI Scans During Radiation Therapy
Reclutant
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prostate Active Surveillance Study
ReclutantEstudi observacional
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
ReclutantFase 2
- Dana Farber Cancer Institute, Boston
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
ReclutantFase 2
- Brigham and Women's Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
ReclutantFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
ReclutantFase 2
- Dana-Farber Cancer Institute / Beth Israel Deaconess Medical Center, Boston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
ReclutantFase 1/2
- Research Site, Boston
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
ReclutantFase 1
- Dana-Farber Cancer Institute, Boston
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
ReclutantFase 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
Reclutant
- Dana Farber Cancer Institute, Boston
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
ReclutantFase 3
- Dana-Farber Cancer Institute, Boston
Jump: MR Simulation For Radiation Therapy Master Protocol
Reclutant
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
ReclutantFase 1
- Dana Farber Cancer Institute, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
ReclutantFase 1
- Dana Farber Cancer Institute, Boston
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
ReclutantFase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Video Education With Result Dependent dIsclosure
Reclutant
- Dana Farber Cancer Institute, Boston
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
ReclutantFase 3
- Brigham and Women's Hospital, Boston
- Brigham and Women's Faulkner Hospital, Boston
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
ReclutantEstudi observacional
- Dana-Farber Cancer Institute, Boston
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Massachusetts General Hospital, Boston
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
ReclutantEstudi observacional
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1
- Research Site, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ReclutantFase 1/2
- Massachusetts General Hospital, Boston
Clinical Trial of Approaches to Prostate Cancer Surgery
Reclutant
- Beth Israel Deaconess Medical Center (BIDMC), Boston
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
ReclutantFase 1/2
- Dana-Farber Cancer Institute, Boston
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
ReclutantFase 2/3
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
ReclutantFase 1
- Dana Farber Cancer Institute, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
ReclutantFase 1/2
- Massachusetts General Hospital, Boston
Study of AZD0754 in Participants With Metastatic Prostate Cancer
ReclutantFase 1/2
- Research Site, Boston
- Research Site, Boston
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
ReclutantFase 4
- Dana Farber Cancer Institute, Boston
- Brigham and Womens Hospital, Boston
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
ReclutantFase 4
- Massachussets General Hospital, Boston
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
ReclutantVoluntaris sans benvinguts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
MRI Guided Prostate Biopsy
Reclutant
- Brigham and Women's Hospital, Boston
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
ReclutantEstudi observacional
- Massachsuetts General Hospital, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
Reclutant
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
ReclutantVoluntaris sans benvinguts
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
ReclutantFase 1
- Dana Farber Cancer Institute, Boston
- Brigham and Womens Hospital, Boston
Comprehensive Outcomes for After Cancer Health
ReclutantVoluntaris sans benvinguts
- Dana Farber Cancer Institute, Boston
ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
ReclutantEstudi observacional
- Massachusetts General Hospital, Boston
Prostate Cancer Genetic Risk Evaluation and Screening Study
ReclutantEstudi observacional
- Massachusetts General Hospital, Boston
Assaigs de Càncer de pròstata en altres ciutats
- New York City, NY103 estudis
- Houston, TX76 estudis
- Los Angeles, CA61 estudis
- St. Louis, MO46 estudis
- Chicago, IL45 estudis
- San Francisco, CA45 estudis
- Philadelphia, PA44 estudis
- Baltimore, MD43 estudis
- Nashville, TN42 estudis
- Seattle, WA42 estudis
- Washington, DC38 estudis
- Dallas, TX36 estudis
Altres estudis a Boston
- Càncer de mama111 estudis
- Càncer de pulmó de cèl·lules no petites90 estudis
- Càncer (tots els tipus)86 estudis
- Càncer colorrectal63 estudis
- Càncer metastàtic63 estudis
- Càncer de pulmó62 estudis
- Càncer d'ovari61 estudis
- Depressió52 estudis
- Càncer d'endometri50 estudis
- Insuficiència cardíaca44 estudis
- Leucèmia mieloide aguda44 estudis
- Càncer de pàncrees43 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.